Source: Annual Congress 2006 - Community-acquired pneumonia: risk factors and treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. C. Read, A. Torres, H. Lode, J. Carlet, J. H. Winter, J. Garau, T. Welte, M. A. Le Berre, J. E. Ambler, S. H. Choudhri, P. Arvis (Sheffield, Dundee, United Kingdom; Barcelona, Spain; Berlin, Hannover, Germany; Paris, Puteaux, France; West Haven, USA). Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP). Eur Respir J 2006; 28: Suppl. 50, 2083

Member's Comments

No comment yet.

Related content which might interest you: Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study) Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Significant decrease in long-term survival for hospitalised patients with community-acquired pneumonia (CAP): results from the community-acquired pneumonia organisation (CAPO) international cohort study Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Clinical stability in patients with community- acquired pneumonia (CAP) Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011 Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Clinical cure rates in patients treated with azithromycin (AZ) for lower respiratory infections (LRTI) caused by AZ-susceptible (AZ-S) and AZ-resistant (AZ-R) organisms: Analysis of phase 3 clinical trials Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 The presence of diabetes does not influence clinical outcomes in patients with community-acquired pneumonia: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Severity scores and comorbidities in community-acquired pneumonia Year: 2007 Clinical factors associated with delayed diagnosis in hospitalized community-acquired pneumonia (CAP). Impact on the outcome Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia Year: 2010 Optimizing treatment for community-acquired pneumonia in Denmark (The optiCAP study) Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Etiology of community-acquired pneumonia (CAP) in young hospital patients Source: Eur Respir J 2002; 20: Suppl. 38, 356s Year: 2002 Comparative analysis of clinical and epidemiological characteristics of patients with CAP (community-acquired pneumonia) treated as inpatients and outpatients Source: Eur Respir J 2006; 28: Suppl. 50, 3s Year: 2006 Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet? Source: Eur Respir J 2013; 41: 5-6 Year: 2013 The pneumonia severity index (PSI) do not underestimate the severity of community-acquired pneumonia (CAP) in young patients: results from the CAPO international study Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Clinical and laboratory predictors of survival in patients with severe community-acquired pneumonia (CAP) Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections Year: 2014